|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.17 CAD | +6.25% |
|
+6.25% | -2.86% |
| Apr. 24 | Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding | CI |
| Apr. 05 | Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent | CI |
Theralase Technologies Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CAD 1.14 million compared to CAD 0.780641 million a year ago. Net loss was CAD 5.24 million compared to CAD 4.41 million a year ago.
Basic loss per share from continuing operations was CAD 0.025 compared to CAD 0.022 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.86% | 29.8M | |
| -19.01% | 255M | |
| -28.35% | 83.74M |
THERALASE TECHNOLOGIES INC. 